NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
In the intent-to-treat population, patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel had an mOS of 16.20 months compared to 14.16 months in patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement (hazard ratio=0.819; On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
周一，爱文思控股有限公司（NASDAQ:NVCR）和再鼎医药有限公司（NASDAQ:ZLAB）公布了第3期PANOVA-3试验的前线数据，该试验评估了将肿瘤治疗电场（TTFields）疗法与吉西他滨和纳帕紫杉醇同时作为不可切除的局部晚期胰腺腺癌的一线治疗。
The pivotal trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control.
该关键试验达到了主要终点，证明了与对照组相比中位总生存期（mOS）具有统计学上显著的改善。
Also Read: FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
另请参阅：FDA批准NovoCure生产便携式设备，为以往接受治疗的肺癌患者产生肿瘤治疗电场
In the intent-to-treat population, patients treated with TTFields therapy concomitant with gemcitabine and nab-paclitaxel had an mOS of 16.20 months compared to 14.16 months in patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement (hazard ratio=0.819; P=0.039) (N=571).
在意图治疗人群中，接受TTFields疗法与吉西他滨和纳帕紫杉醇同时治疗的患者的mOS为16.20个月，而单独接受吉西他滨和纳帕紫杉醇治疗的患者为14.16个月，这是一项统计学上显著的2.0个月的改善（风险比=0.819; P=0.039）（N=571）。
The survival rate benefit for patients treated with TTFields therapy increased over time, with a 13% improvement in the overall survival rate at 12 months and a 33% improvement in survival rate at 24 months.
接受TTFields疗法治疗的患者的生存率益处随时间增加，在12个月时总体生存率提高了13%，在24个月时生存率提高了33%。
TTFields therapy was well-tolerated, and safety was consistent with prior clinical studies. Novocure plans to file for regulatory approval in the U.S., EU, Japan and other key markets. Zai Lab plans to file for regulatory approval in China.
TTFields疗法耐受性良好，安全性与先前的临床研究一致。爱文思控股计划在美国、欧盟、日本和其他关键市场申请监管批准。再鼎医药计划在中国申请监管批准。
Novocure continues to follow patients in its Phase 2 PANOVA-4 trial, which is exploring the use of TTFields therapy together with atezolizumab, gemcitabine, and nab-paclitaxel for the treatment of metastatic pancreatic cancer. PANOVA-4 has completed enrollment, and data are anticipated in 2026.
爱文思控股继续追踪其第2期PANOVA-4试验中的患者，该试验探索了将TTFields疗法与阿特珠单抗、吉西他滨和纳帕紫杉醇结合治疗转移性胰腺癌。 PANOVA-4已完成招募，并预计将于2026年公布数据。
Price Action: NVCR stock is up 31% at $26.26 at last check Monday.
价格走势：NVCR股票在上周一最后一次检查时涨幅为31%，报26.26美元。
- Amazon And Walmart Dominate Black Friday As Online Sales Soar 14.6%
- 亚马逊和沃尔玛主导黑色星期五，随着在线销售飙升14.6%
Photo via Shutterstock.
图片来自shutterstock。
